Mitsubishi UFJ Asset Management Increases Stake in Regeneron Pharmaceuticals

Institutional investor now owns over $121 million in shares of the biopharmaceutical company.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Mitsubishi UFJ Asset Management Co. Ltd., an institutional investor, has increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the third quarter. The firm now owns 216,169 shares of the biopharmaceutical company's stock, valued at approximately $121.55 million.

Why it matters

Regeneron Pharmaceuticals is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of therapies. The increase in Mitsubishi UFJ Asset Management's stake suggests the firm's confidence in Regeneron's long-term growth potential.

The details

According to the company's disclosure with the Securities and Exchange Commission (SEC), Mitsubishi UFJ Asset Management Co. Ltd. purchased an additional 7,106 shares of Regeneron Pharmaceuticals during the third quarter. This brings the firm's total ownership to approximately 0.21% of the company's outstanding shares.

  • Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals during the third quarter of 2026.

The players

Mitsubishi UFJ Asset Management Co. Ltd.

An institutional investor and asset management firm.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The increase in Mitsubishi UFJ Asset Management's stake in Regeneron Pharmaceuticals reflects the firm's confidence in the biopharmaceutical company's long-term growth prospects and its innovative drug discovery capabilities.